Literature DB >> 25519751

How I use fibrinogen replacement therapy in acquired bleeding.

Jerrold H Levy1, Lawrence T Goodnough2.   

Abstract

Fibrinogen is a critical protein for hemostasis and clot formation. However, transfusion guidelines have variable recommendations for maintaining fibrinogen levels in bleeding patients. An increasing number of studies support the practice of fibrinogen replacement therapy for acquired coagulopathies, and additional studies are underway. Fibrinogen therapy can be administered with cryoprecipitate or fibrinogen concentrates, and clinical practice varies according to their availability and licensing status. Fibrinogen concentrate therapy has been studied in animal models and clinical trials and supports the critical role of fibrinogen repletion in bleeding patients. Point-of-care testing will have an important role in guiding fibrinogen replacement for hemostatic therapy in clinical settings such as cardiovascular surgery, postpartum hemorrhage, and trauma. Fibrinogen therapy is an important component of a multimodal strategy for the treatment of coagulopathic bleeding.
© 2015 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25519751     DOI: 10.1182/blood-2014-08-552000

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  27 in total

Review 1.  Reducing transfusion requirements in liver transplantation.

Authors:  Ciara I Donohue; Susan V Mallett
Journal:  World J Transplant       Date:  2015-12-24

2.  Effects of in-house cryoprecipitate on transfusion usage and mortality in patients with multiple trauma with severe traumatic brain injury: a retrospective cohort study.

Authors:  Kazuhiro Sugiyama; Hiroshi Fujita; Shigeko Nishimura
Journal:  Blood Transfus       Date:  2019-01-22       Impact factor: 3.443

3.  Adhesion of Blood Clots Can Be Enhanced When Copolymerized with a Macromer That Is Crosslinked by Coagulation Factor XIIIa.

Authors:  Karen Y T Chan; Chunyi Zhao; Erika M J Siren; Jeanne C Y Chan; Jeffrey Boschman; Christian J Kastrup
Journal:  Biomacromolecules       Date:  2016-05-17       Impact factor: 6.988

4.  Characteristics of thawed pooled cryoprecipitate stored at refrigerated temperature for 24 hours.

Authors:  Esther P Soundar; Meredith Reyes; Laura Korte; Arthur Bracey
Journal:  Blood Transfus       Date:  2017-10-30       Impact factor: 3.443

5.  Thromboembolic events in patients with severe inherited fibrinogen deficiency.

Authors:  Amihai Rottenstreich; Avigal Lask; Lilliana Schliamser; Ariella Zivelin; Uri Seligsohn; Yosef Kalish
Journal:  J Thromb Thrombolysis       Date:  2016-08       Impact factor: 2.300

6.  The European guideline on management of major bleeding and coagulopathy following trauma: fifth edition.

Authors:  Donat R Spahn; Bertil Bouillon; Vladimir Cerny; Jacques Duranteau; Daniela Filipescu; Beverley J Hunt; Radko Komadina; Marc Maegele; Giuseppe Nardi; Louis Riddez; Charles-Marc Samama; Jean-Louis Vincent; Rolf Rossaint
Journal:  Crit Care       Date:  2019-03-27       Impact factor: 9.097

Review 7.  Perioperative management of the bleeding patient.

Authors:  K Ghadimi; J H Levy; I J Welsby
Journal:  Br J Anaesth       Date:  2016-12       Impact factor: 9.166

Review 8.  Biomaterials and Advanced Technologies for Hemostatic Management of Bleeding.

Authors:  DaShawn A Hickman; Christa L Pawlowski; Ujjal D S Sekhon; Joyann Marks; Anirban Sen Gupta
Journal:  Adv Mater       Date:  2017-11-22       Impact factor: 30.849

9.  Fibrinogen Albumin Ratio and Ischemic Stroke During Venoarterial Extracorporeal Membrane Oxygenation.

Authors:  Prakash Acharya; William A Jakobleff; Stephen J Forest; Thiru Chinnadurai; Nicolas Mellas; Snehal R Patel; Jorge R Kizer; Henny H Billett; Daniel J Goldstein; Ulrich P Jorde; Omar Saeed
Journal:  ASAIO J       Date:  2020-03       Impact factor: 3.826

10.  Fibrinogen Activates PAK1/Cofilin Signaling Pathway to Protect Endothelial Barrier Integrity.

Authors:  Feng Wu; Amanda Chipman; Jing-Fei Dong; Rosemary Ann Kozar
Journal:  Shock       Date:  2021-05-01       Impact factor: 3.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.